Table 1.
Demographics and characteristics of pediatric patients with solid tumors and lymphoma who underwent an autologous HSCT at SJCRH between 1990 and 2009
| Characteristic | 1990–1999 n=128 |
2000–2009 n=192 |
1990–2009 n=320 |
P-value |
|---|---|---|---|---|
| Mean age in years | 9.0 | 8.3 | 8.6 | 0.80 |
| 0–<2 | 9 (7) | 16 (8) | 25 (8) | |
| 2– <10 | 68 (53) | 108 (56) | 176 (55) | |
| >10 | 51 (40) | 68 (35) | 119 (37) | |
| Males | 85 (66) | 115 (60) | 200 (63) | 0.29 |
| Race | 0.41 | |||
| White | 102 (80) | 145 (76) | 247 (77) | |
| AA | 23 (18) | 37 (19) | 60 (19) | |
| Others | 3 (2) | 10 (5) | 13 (4) | |
| Diagnosis | 0.69 | |||
| Solid tumor | 98 (77) | 143 (74) | 241 (75) | |
| NB | 62 (48) | 88 (46) | 150 (47) | |
| EWS | 3 (2) | 19 (10) | 22 (7) | |
| RMS | 6 (5) | 1 (1) | 7 (2) | |
| Others | 27 (21) | 34 (18) | 61 (1) | |
| Pineoblastoma | 0 (0) | 1 (1) | 1 (<1) | |
| Lymphoma | 30 (23) | 49 (26) | 79 (25) | |
| HD | 12 (9) | 35 (18) | 47 (15) | |
| NHL | 18 (14) | 14 (7) | 32 (10) | |
| Disease status | 1.00 | |||
| Remission | 50 (39) | 74 (39) | 124 (39) | |
| Non-remission1 | 78 (61) | 118 (61) | 196 (61) | |
| Product type | <0.0001 | |||
| HPC-A | 30 (23) | 133 (69) | 163 (51) | |
| HPC-M | 98 (77) | 59 (31) | 157 (49) | |
| CMV status | 0.001 | |||
| Positive | 50 (39) | 115 (60) | 165 (52) | |
| Negative | 72 (56) | 77 (40) | 149 (47) | |
| NA | 6 (5) | 0 (0) | 6 (2) | |
| Time to engraftment2 | <0.0001 | |||
| Within 28 days | 101 (79) | 185 (96) | 286 (89) | |
| After 28 days | 24 (19) | 7 (4) | 31 (10) |
Data are no. (%) of patients, unless otherwise indicated
1
Includes patients with very good partial response, partial response to chemotherapy, stable, and progressive disease.
2
Three patients failed to engraft 1990–1999.
HSCT, hematopoietic stem cell transplantation; SJCRH, St. Jude Children’s Research Hospital; AA, African-American; NB, neuroblastoma; EWS, Ewing’s sarcoma; RMS, rhabdomyosarcoma; HD, Hodgkin’s disease; NHL, non-Hodgkin’s lymphoma; HPC-A/M, human progenitor cells-apheresis/-marrow; CMV, cytomegalovirus; NA, not available.